ArticleCell reports. Medicine2024
The gut-brain axis in depression: Are multi-omics showing the way?
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sotagliflozin pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities and modulates the gut microbiota-immune-brain axis.Psychopharmacology · 2026Article
- Clozapine disrupts the gut-lung microbiota axis, linking gastrointestinal hypomotility to increased respiratory vulnerability.Translational psychiatry · 2026Article
- A Novel Integrative Framework for Depression: Combining Network Pharmacology, Artificial Intelligence, and Multi-Omics with a Focus on the Microbiota-Gut-Brain Axis.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is time for a paradigm shift in psychiatry. The need for biologically based models to understand clinical heterogeneity is gaining momentum. Integrating the microbiome into biomarker discovery provides an accessible, biological approach to generate clinically relevant biomarkers that consider the host and the environment in a comprehensive way.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.